Noveris Health SciencesMYCOF 23 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates MYCOF with a GF Score™ of 23/100. Among 684 Drug Manufacturers companies, Noveris Health Sciences ranks worse than 146198.68% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Noveris Health Sciences's
Operating Income
for the
three
months ended in Mar. 2026 was $-0.23 Mil. Noveris Health Sciences's Interest Expense for the
three
months ended in Mar. 2026 was $-0.01 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Noveris Health Sciences's Interest Coverage or its related term are showing as below:
MYCOF's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.765 * Ranked among companies with meaningful Interest Coverage only.
Noveris Health Sciences (OTCPK:MYCOF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Noveris Health Sciences Interest Coverage Related Terms
Noveris Health Sciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for Noveris Health Sciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's Interest Coverage falls into.
Noveris Health Sciences Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Noveris Health Sciences did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Noveris Health Sciences (MYCOF) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Noveris Health Sciences and its competitors. According to the industry distribution chart, Noveris Health Sciences ranks #999999 out of 684 companies in the Drug Manufacturers industry.
Is Noveris Health Sciences' Interest Coverage too high?
Noveris Health Sciences' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Noveris Health Sciences ranks #999999 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Noveris Health Sciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #999999 out of 684 companies for Interest Coverage. This places Noveris Health Sciences in the lower half of its industry. The industry median Interest Coverage is 12.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Noveris Health Sciences (MYCOF) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score
Get the complete analysis for MYCOF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
